TND-1128

TND-1128 was engineered by adding lipophilicity to the 5-deazaflavin core so that the molecule can enter cells and reach mitochondria, where its self-redox chemistry can feed electron-transfer reactions. Studies from Tokyo Medical University and collaborators used mouse brain slices to show that pretreatment with TND1128 raises mitochondrial membrane potential and increases an ATP synthesis index in a dose- and time-dependent manner ^[2].

In a comparative study, TND1128 (0.01-1 mg/kg subcutaneously) mitigated calcium overload in both cytoplasm and mitochondria of neurons during repeated depolarising stress, and at these low doses it outperformed beta-NMN (nicotinamide mononucleotide) on mitochondrial calcium handling ^[1]. The authors framed TND1128 as a candidate for rescuing deteriorating neurons in aging and in diseases such as Alzheimer type dementia.

Additional preprint work reports that TND1128 and hybrid analogs are cytoprotective against hydrogen peroxide induced oxidative stress ^[3]. All current evidence is preclinical; there are no human clinical trials, and the antidepressant and neuroprotective framing derives from mechanism and animal-tissue findings rather than from patient data.

TND-1128 is an experimental, preclinical compound. Its safety has been assessed only in cell and rodent-tissue studies at low milligram-per-kilogram doses; there are no human safety, tolerability or long-term data. Purity, dosing and interactions for human use are undefined, and it should be regarded as a research chemical rather than a validated supplement. Anyone considering it should recognise the absence of clinical evidence and consult a healthcare professional.

TND-1128 emerged from Japanese medicinal chemistry efforts to turn the naturally redox-active 5-deazaflavin scaffold into a cell-permeable mitochondrial activator. Groups associated with Tokyo Medical University, Sojo University and Kumamoto Kinoh Hospital published the principal characterisations between 2022 and 2024, motivated by the idea that reactivating dysfunctional mitochondria could slow neuronal decline in aging and neuropsychiatric disease.

In nootropic circles TND-1128 is discussed as a cutting-edge mitochondrial enhancer, sometimes compared favourably with NMN for neuronal energy support based on the low-dose rodent findings. That reputation rests on a small but coherent Japanese preclinical literature; it has no clinical validation, and marketing claims about mood or cognition in humans are extrapolations.